

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes	
J8700	Temozolomide	5 MG	11.217									
J8705	Topotecan oral	0.25 mg	86.641									
J9000	Doxorubicin hcl injection	10 MG	3.667									
J9010	Alemtuzumab injection	10 MG	623.633									
J9017	Arsenic trioxide injection	1 MG	47.406									
J9019	Erwinaze injection	1,000 IU	342.738									
J9020	Asparaginase, NOS	10000 UNITS	64.565									
J9025	Azacitidine injection	1 MG	5.768									
J9027	Clofarabine injection	1 MG	129.206									
J9031	Bcg live intravesical vac	1 EA	119.296									
J9033	Bendamustine injection	1 MG	20.820									
J9035	Bevacizumab injection	10 MG	64.643									
J9040	Bleomycin sulfate injection	15 UNITS	20.485		95	289.370						
J9041	Bortezomib injection	0.1 MG	45.330									
J9042	Brentuximab vedotin inj	1 MG	102.741									
J9043	Cabazitaxel injection	1 MG	139.728									
J9045	Carboplatin injection	50 MG	2.974									
J9050	Carmustine injection	100 MG	175.298									
J9055	Cetuximab injection	10 MG	52.479									
J9060	Cisplatin 10 MG injection	10 MG	1.835									
J9065	Inj cladribine per 1 MG	1 MG	25.978		95	61.720						
J9070	Cyclophosphamide 100 MG inj	100 MG	40.375									
J9098	Cytarabine liposome inj	10 MG	544.227									
J9100	Cytarabine hcl 100 MG inj	100 MG	0.942		95	8.190						
J9120	Dactinomycin injection	0.5 MG	618.792									
J9130	Dacarbazine 100 mg inj	100 MG	4.056									
J9150	Daunorubicin injection	10 MG	28.734									
J9155	Degarelix injection	1 MG	3.046									
J9160	Denileukin diftitox inj	300 MCG	1646.180									
J9171	Docetaxel injection	1 MG	4.762									
J9175	Elliotts b solution per ml	1 ML	4.074									
J9178	Inj, epirubicin hcl, 2 mg	2 MG	1.341									
J9179	Eribulin mesylate injection	0.1 MG	97.920									
J9181	Etoposide injection	10 MG	0.752									
J9185	Fludarabine phosphate inj	50 MG	88.528									
J9190	Fluorouracil injection	500 MG	2.117		95	2,070						
J9200	Floxuridine injection	500 MG	64.130		95	136.800						
J9201	Gemcitabine hcl injection	200 MG	5.667									
J9202	Goserelin acetate implant	3.6 MG	189.543									
J9206	Irinotecan injection	20 MG	2.246									
J9207	Ixabepilone injection	1 MG	67.661									
J9208	Ifosfamide injection	1 GM	30.266		95	150.380						

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes
J9209	Mesna injection	200 MG	2.840								
J9211	Idarubicin hcl injection	5 MG	43.759								AMP-based payment limit
J9214	Interferon alfa-2b inj	1 MIL UNITS	18.800								AMP-based payment limit
J9217	Leuprolide acetate suspnsion	7.5 MG	206.013								
J9218	Leuprolide acetate injeciton	1 MG	10.497								
J9225	Vantas implant	50 MG	2994.405								
J9226	Suprelin LA implant	50 MG	16424.128								
J9228	Ipilimumab injection	1 MG	127.045								
J9230	Mechlorethamine hcl inj	10 MG	157.613								
J9245	Inj melphalan hydrochl 50 MG	50 MG	1273.103								
J9250	Methotrexate sodium inj	5 MG	0.272								
J9260	Methotrexate sodium inj	50 MG	2.757								
J9261	Nelarabine injection	50 MG	127.282								
J9263	Oxaliplatin	0.5 MG	0.876								
J9264	Paclitaxel protein bound	1 MG	9.539								
J9265	Paclitaxel injection	30 MG	4.107								
J9266	Pegaspargase injection	1 EA	6004.741								
J9268	Pentostatin injection	10 MG	1399.285								
J9280	Mitomycin injection	5 MG	23.989								
J9293	Mitoxantrone hydrochl / 5 MG	5 MG	37.174								
J9300	Gemtuzumab ozogamicin inj	5 MG	2742.591								
J9302	Ofatumumab injection	10 MG	46.500								
J9303	Panitumumab injection	10 MG	91.099								
J9305	Pemetrexed injection	10 MG	59.481								
J9307	Pralatrexate injection	1 MG	182.579								
J9310	Rituximab injection	100 MG	678.865								
J9315	Romidepsin injection	1 MG	253.470								
J9320	Streptozocin injection	1 GM	276.049								
J9328	Temozolamide injection	1 MG	4.841								
J9330	Tensirolimus injection	1 MG	55.950								
J9340	Thiotepa injection	15 MG	265.000								
J9351	Topotecan injection	0.1 MG	2.132								
J9355	Trastuzumab injection	10 MG	78.697		95	58.130					
J9357	Valrubicin injection	200 MG	1054.483								
J9360	Vinblastine sulfate inj	1 MG	1.624		95	4.100					
J9370	Vincristine sulfate 1 MG inj	1 MG	4.422		95	33.980					
J9390	Vinorelbine tartrate inj	10 MG	10.233								
J9395	Injection, Fulvestrant	25 MG	89.620								
P9041	Albumin (human),5%, 50ml	50 ML	9.546				95	9.546			
P9043	Plasma protein fract,5%,50ml	50 ML	8.333				95	8.333			
P9045	Albumin (human), 5%, 250 ml	250 ML	47.728				95	47.728			
P9046	Albumin (human), 25%, 20 ml	20 ML	19.680				95	19.680			

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective July 1, 2013 through September 30, 2013

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q13 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.